Analysts’ Recent Ratings Changes for TherapeuticsMD (TXMD)

A number of research firms have changed their ratings and price targets for TherapeuticsMD (NASDAQ: TXMD):

  • 11/2/2018 – TherapeuticsMD was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
  • 11/1/2018 – TherapeuticsMD was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/29/2018 – TherapeuticsMD was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/29/2018 – TherapeuticsMD was given a new $27.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/24/2018 – TherapeuticsMD was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “sell” rating. According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
  • 10/17/2018 – TherapeuticsMD was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.25 price target on the stock. According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
  • 10/14/2018 – TherapeuticsMD was given a new $27.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/2/2018 – TherapeuticsMD was given a new $14.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 9/27/2018 – TherapeuticsMD was given a new $27.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 9/26/2018 – TherapeuticsMD was given a new $14.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 9/21/2018 – TherapeuticsMD was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/7/2018 – TherapeuticsMD was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of TherapeuticsMD stock opened at $5.00 on Monday. The company has a current ratio of 7.88, a quick ratio of 7.79 and a debt-to-equity ratio of 0.94. TherapeuticsMD Inc has a 52 week low of $4.30 and a 52 week high of $7.66. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -13.51 and a beta of 1.40.

In other TherapeuticsMD news, CEO Robert G. Finizio sold 184,000 shares of the business’s stock in a transaction dated Friday, October 26th. The shares were sold at an average price of $5.28, for a total value of $971,520.00. Following the sale, the chief executive officer now directly owns 18,485,559 shares in the company, valued at $97,603,751.52. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brian Bernick sold 182,800 shares of the business’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $6.30, for a total transaction of $1,151,640.00. Following the completion of the sale, the director now owns 242,000 shares in the company, valued at $1,524,600. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,158,800 shares of company stock worth $12,946,562. 22.85% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the business. OppenheimerFunds Inc. raised its position in TherapeuticsMD by 17.4% in the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock worth $12,058,000 after acquiring an additional 286,123 shares in the last quarter. BlackRock Inc. raised its holdings in TherapeuticsMD by 4.4% during the 2nd quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock worth $90,690,000 after buying an additional 608,470 shares during the period. Xact Kapitalforvaltning AB raised its holdings in TherapeuticsMD by 96.3% during the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock worth $155,000 after buying an additional 15,600 shares during the period. Public Employees Retirement Association of Colorado raised its holdings in TherapeuticsMD by 2,545.7% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock worth $6,686,000 after buying an additional 1,031,000 shares during the period. Finally, Twin Focus Capital Partners LLC acquired a new stake in TherapeuticsMD during the 2nd quarter worth about $187,000. Hedge funds and other institutional investors own 66.13% of the company’s stock.

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Read More: Yield Curve

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply